AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14670700 — intervention group
Group type: EXPERIMENTAL
Intervention: Contours displayed in isolation
Number of subjects: 0
Study 14670700 — intervention group
Group type: EXPERIMENTAL
Intervention: Contours displayed within face-like contexts (cartoon faces)
Number of subjects: 0
Study 9884178 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 500
Study 9884178 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (not specified)
Number of subjects: 500
Study 7617626 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus electrophoresis and UV blood irradiation (group 1)
Number of subjects: 222
Study 7617626 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (group 2)
Number of subjects: 222
Study 7617626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (group 1)
Number of subjects: 222
Study 2651492 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA 75 mg sustained release
Number of subjects: 837
Study 2651492 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA 25 mg
Number of subjects: 837
Study 2651492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 837
Study 63128 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined audio-video channel
Number of subjects: 20
Study 63128 — intervention group
Group type: COMPARATOR
Intervention: Audio channel
Number of subjects: 20
Study 63128 — intervention group
Group type: COMPARATOR
Intervention: Video channel
Number of subjects: 20
Study 63128 — intervention group
Group type: COMPARATOR
Intervention: Audio followed by video (version b)
Number of subjects: 20
Study 63128 — intervention group
Group type: EXPERIMENTAL
Intervention: Video followed by audio (version a)
Number of subjects: 20
Study 31757429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 160
Study 30547316 — intervention group
Group type: EXPERIMENTAL
Intervention: F14512 at dose level 10 mg/m2/day
Number of subjects: 11
Study 30547316 — intervention group
Group type: EXPERIMENTAL
Intervention: F14512 at dose level 5 mg/m2/day
Number of subjects: 11
Study 30547316 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient outcomes
Number of subjects: 11
Study 28855568 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rGH)
Number of subjects: 0
Study 28855568 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 25851025 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Iranian Pharmacy formulation
Number of subjects: 0
Study 25851025 — intervention group
Group type: COMPARATOR
Intervention: Marketed formulation
Number of subjects: 0
Study 23697964 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 50
Study 23697964 — intervention group
Group type: COMPARATOR
Intervention: Control (non-RDN)
Number of subjects: 50
Study 21462059 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST), 1 to 8 sessions, 45 minutes each with a social worker
Number of subjects: 107
Study 19686597 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 315
Study 19686597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 16787129 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavior change program
Number of subjects: 0
Study 15303109 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP)
Number of subjects: 50
Study 15303109 — intervention group
Group type: COMPARATOR
Intervention: Medium-protein diet (MP)
Number of subjects: 50
Study 11045895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Number of subjects: 43
Study 11045895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9308139 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) delivered inside the Gamow bag with a demand valve regulator mask at a Po2 of 1.58 atm abs for 40 min.
Number of subjects: 12
Study 9308139 — intervention group
Group type: COMPARATOR
Intervention: Normobaric oxygen (NBO2) using a non-rebreather mask at a rate of 15 liter/min outside the Gamow bag for 40 min.
Number of subjects: 12
Study 9308139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HBO2 and NBO2 were tested for COHb elimination kinetics.
Number of subjects: 12
Study 8346588 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU Salcatonin
Number of subjects: 208
Study 8346588 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU Salcatonin
Number of subjects: 208
Study 8346588 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU Salcatonin
Number of subjects: 208
Study 8346588 — intervention group
Group type: COMPARATOR
Intervention: Calcium (placebo)
Number of subjects: 208
Study 8346588 — intervention group
Group type: EXPERIMENTAL
Intervention: Salcatonin (any dose)
Number of subjects: 208
Study 8346588 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 208
Study 29718143 — intervention group
Group type: EXPERIMENTAL
Intervention: Covering empirical antibiotic treatment (EAT)
Number of subjects: 406
Study 29718143 — intervention group
Group type: COMPARATOR
Intervention: Noncovering empirical antibiotic treatment (EAT)
Number of subjects: 406
Study 29718143 — intervention group
Group type: EXPERIMENTAL
Intervention: Covering EAT
Number of subjects: 406
Study 29718143 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin monotherapy and colistin-carbapenem combination EAT
Number of subjects: 406
Study 29718143 — intervention group
Group type: EXPERIMENTAL
Intervention: Covering antibiotics in propensity score-matched cohort (n = 338)
Number of subjects: 406
Study 29718143 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day mortality analysis
Number of subjects: 406
Study 26999280 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory Factor Analysis (EFA)
Number of subjects: 270
Study 26999280 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory Factor Analysis (CFA)
Number of subjects: 270
Study 26999280 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-order psychopathology construct
Number of subjects: 270
Study 26999280 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal assessment
Number of subjects: 270
Study 24344211 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN‐α‐2b) 20 MIU/m(2) intravenously (IV) daily 5 days per week for 4 weeks (arm A)
Number of subjects: 194
Study 24344211 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b (IFN‐α‐2b) 20 MIU/m(2) intravenously (IV) daily 5 days per week for 4 weeks followed by IFN‐α‐2b 10 MIU/m(2) administered subcutaneously three times per week for 48 weeks (arm B)
Number of subjects: 194
Study 22987303 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (100 ml three times daily)
Number of subjects: 80
Study 22987303 — intervention group
Group type: COMPARATOR
Intervention: Water (100 ml three times daily)
Number of subjects: 80
Study 20570659 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal working memory (digit identity)
Number of subjects: 0
Study 20570659 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial working memory (digit location)
Number of subjects: 0
Study 20570659 — intervention group
Group type: EXPERIMENTAL
Intervention: High CE-demand conditions
Number of subjects: 0
Study 18678800 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg of transdermal estradiol
Number of subjects: 102
Study 18678800 — intervention group
Group type: COMPARATOR
Intervention: transdermal placebo
Number of subjects: 102
Study 16448248 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Cure (MC) adhesive
Number of subjects: 112
Study 16448248 — intervention group
Group type: COMPARATOR
Intervention: Filtek Flow (FF) adhesive
Number of subjects: 112
Study 16448248 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Cure (MC) adhesive (maxillary arch)
Number of subjects: 112
Study 16448248 — intervention group
Group type: COMPARATOR
Intervention: Filtek Flow (FF) adhesive (maxillary arch)
Number of subjects: 112
Study 16448248 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Cure (MC) adhesive (mandibular arch)
Number of subjects: 112
Study 16448248 — intervention group
Group type: COMPARATOR
Intervention: Filtek Flow (FF) adhesive (mandibular arch)
Number of subjects: 112
Study 12578931 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease (AD) patients
Number of subjects: 44
Study 12578931 — intervention group
Group type: COMPARATOR
Intervention: Cognitively Normal (CN) subjects
Number of subjects: 44
Study 12578931 — intervention group
Group type: COMPARATOR
Intervention: Baseline volume of ERC in CN subjects
Number of subjects: 44
Study 12578931 — intervention group
Group type: EXPERIMENTAL
Intervention: ERC baseline volumes and annual atrophy rate
Number of subjects: 44
Study 10368839 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor and flexor muscle training
Number of subjects: 36
Study 8697293 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (295 μg/kg)
Number of subjects: 6
Study 1855093 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic BMT
Number of subjects: 340
Study 1855093 — intervention group
Group type: COMPARATOR
Intervention: Autologous BMT
Number of subjects: 340
Study 1855093 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 340
Study 6319151 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 7.00 h in winter
Number of subjects: 6
Study 6319151 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 14.00 h in summer
Number of subjects: 6
Study 6319151 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 7.00 h in winter and summer
Number of subjects: 6
Study 6319151 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 analogue (100 micrograms i.m.) administered at 21.00 h
Number of subjects: 6
Study 31256289 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanteric impaction (TI) with femoral offset (FO) loss
Number of subjects: 42
Study 31256289 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mechanical failure)
Number of subjects: 42
Study 30252521 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS education plus hands‐on CRS installation training
Number of subjects: 6
Study 30252521 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS education only
Number of subjects: 6
Study 30252521 — intervention group
Group type: COMPARATOR
Intervention: Control (child electricity safety)
Number of subjects: 6
Study 27166651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar, Heart, and Life (SHL) application
Number of subjects: 123
Study 25321341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian method for electron density mapping
Number of subjects: 8
Study 25321341 — intervention group
Group type: COMPARATOR
Intervention: Deformable registration
Number of subjects: 8
Study 25321341 — intervention group
Group type: COMPARATOR
Intervention: Intensity approach based on T1
Number of subjects: 8
Study 25321341 — intervention group
Group type: COMPARATOR
Intervention: No density correction (set whole head to water)
Number of subjects: 8
Study 25321341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian method for bone detection
Number of subjects: 8
Study 25321341 — intervention group
Group type: COMPARATOR
Intervention: Deformable registration for bone detection
Number of subjects: 8
Study 25321341 — intervention group
Group type: COMPARATOR
Intervention: Intensity approach for bone detection
Number of subjects: 8
Study 25321341 — intervention group
Group type: COMPARATOR
Intervention: No density correction for bone detection
Number of subjects: 8
Study 25321341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian method robustness
Number of subjects: 8
Study 22185621 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC (alcoholic beverage containing 1 g·kg(‐1) body weight)
Number of subjects: 23
Study 22185621 — intervention group
Group type: COMPARATOR
Intervention: OJ (nonalcoholic beverage)
Number of subjects: 23
Study 22185621 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC (alcoholic beverage)
Number of subjects: 23
Study 22185621 — intervention group
Group type: EXPERIMENTAL
Intervention: EX OJ (nonalcoholic beverage after eccentric exercise)
Number of subjects: 23
Study 22185621 — intervention group
Group type: EXPERIMENTAL
Intervention: EX ALC (alcoholic beverage after eccentric exercise)
Number of subjects: 23
Study 22185621 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (EX OJ and EX ALC)
Number of subjects: 23
Study 20829420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound group
Number of subjects: 218
Study 20829420 — intervention group
Group type: COMPARATOR
Intervention: Clinical group
Number of subjects: 218
Study 18510263 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400-800 mg/day)
Number of subjects: 0
Study 18510263 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (300 mg on day 1, 600 mg on day 2, 800 mg on day 3)
Number of subjects: 0
Study 18510263 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400-800 mg/day once-daily)
Number of subjects: 0
Study 18510263 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 0
Study 18510263 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (600 mg/day and 800 mg/day)
Number of subjects: 0
Study 18510263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16263889 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention programs with exercise components
Number of subjects: 21295
Study 16263889 — intervention group
Group type: EXPERIMENTAL
Intervention: Programs that included risk factor education or counseling with structured exercise
Number of subjects: 21295
Study 16263889 — intervention group
Group type: EXPERIMENTAL
Intervention: Programs that included risk factor education or counseling without exercise
Number of subjects: 21295
Study 16263889 — intervention group
Group type: EXPERIMENTAL
Intervention: Programs that were solely exercise-based
Number of subjects: 21295
Study 11943692 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intervention group
Number of subjects: 0
Study 11943692 — intervention group
Group type: EXPERIMENTAL
Intervention: High intervention group
Number of subjects: 0
Study 11943692 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9535215 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) serum levels
Number of subjects: 75
Study 9535215 — intervention group
Group type: EXPERIMENTAL
Intervention: High Lp(a) serum levels
Number of subjects: 75
Study 9535215 — intervention group
Group type: EXPERIMENTAL
Intervention: High Lp(a) serum levels and IL-6
Number of subjects: 75
Study 9535215 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid profile
Number of subjects: 75
Study 7710151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment (2.8 ATA for 30 minutes followed by 2.0 ATA oxygen for 90 minutes)
Number of subjects: 60
Study 7710151 — intervention group
Group type: COMPARATOR
Intervention: Ambient pressure 100% oxygen treatment
Number of subjects: 60
Study 7710151 — intervention group
Group type: COMPARATOR
Intervention: Control group matched according to age and education level
Number of subjects: 60
Study 2683715 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (20% of calories)
Number of subjects: 21
Study 2683715 — intervention group
Group type: COMPARATOR
Intervention: High-amylose cornstarch (20% of calories)
Number of subjects: 21
Study 197444 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg i.m. ACTH4-10
Number of subjects: 20
Study 197444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31524923 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 electronic health record displayed at a time
Number of subjects: 1200
Study 31524923 — intervention group
Group type: COMPARATOR
Intervention: 4 electronic health records displayed at a time
Number of subjects: 1200
Study 29716670 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 30 mg/day
Number of subjects: 104
Study 29716670 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 75 mg/day
Number of subjects: 104
Study 29716670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 29716670 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (composite groups)
Number of subjects: 104
Study 27220737 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinchen Zhufu Decoction (YCZFD) and Western medicine (WM)
Number of subjects: 200
Study 24630935 — intervention group
Group type: EXPERIMENTAL
Intervention: 100%CAPS
Number of subjects: 15
Study 24630935 — intervention group
Group type: EXPERIMENTAL
Intervention: 75%CAPS
Number of subjects: 15
Study 22341380 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of hypertonic saline before airway clearance techniques
Number of subjects: 50
Study 22341380 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of hypertonic saline during airway clearance techniques
Number of subjects: 50
Study 22341380 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of hypertonic saline after airway clearance techniques
Number of subjects: 50
Study 21126615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemic patients with MS (n = 284)
Number of subjects: 1410
Study 21126615 — intervention group
Group type: COMPARATOR
Intervention: Normouricemic patients with MS (n = 1,126)
Number of subjects: 1410
Study 21126615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemic patients with MS
Number of subjects: 1410
Study 17438178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg 3 times daily)
Number of subjects: 26
Study 17438178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 16280344 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 16280344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11918933 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple randomisation
Number of subjects: 200
Study 11918933 — intervention group
Group type: EXPERIMENTAL
Intervention: Urn randomisation
Number of subjects: 200
Study 11918933 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed randomisation approach
Number of subjects: 200
Study 11918933 — intervention group
Group type: EXPERIMENTAL
Intervention: Permuted-block randomisation
Number of subjects: 200
Study 10428523 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (subcutaneous depot injections for six months)
Number of subjects: 269
Study 10428523 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (surgery only)
Number of subjects: 269
Study 10428523 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 269
Study 10428523 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 269
Study 7473835 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of beta-carotene supplementation for 3 months
Number of subjects: 101
Study 7473835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 2328310 — intervention group
Group type: COMPARATOR
Intervention: Half-strength formulation (25 mg hydrochlorothiazide and 37.5 mg triamterene)
Number of subjects: 0
Study 2328310 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength formulation (50 mg hydrochlorothiazide and 75 mg triamterene)
Number of subjects: 0
Study 7029384 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly chemotherapy
Number of subjects: 133
Study 7029384 — intervention group
Group type: COMPARATOR
Intervention: Poly chemotherapy + unspecific immunotherapy with MER
Number of subjects: 133
Study 7029384 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 133
Study 31650358 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider estimate
Number of subjects: 176
Study 31650358 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week vitamin practice trials
Number of subjects: 176
Study 31650358 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report (HIV Medication Readiness Scale; Transtheoretical Stages of Change item)
Number of subjects: 176
Study 31650358 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance of provider estimate
Number of subjects: 176
Study 31650358 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean dose‐taking adherence
Number of subjects: 176
Study 31650358 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of optimal adherence
Number of subjects: 176
Study 31004164 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 43
Study 31004164 — intervention group
Group type: COMPARATOR
Intervention: Rote rehearsal
Number of subjects: 43
Study 28150044 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst-case scenario (WCS) exercise homework adherence
Number of subjects: 10
Study 28150044 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst-case scenario (WCS) exercise
Number of subjects: 10
Study 28150044 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of FCR
Number of subjects: 10
Study 25798568 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair (pMVR) using the MitraClip system plus optimal medical therapy (OMT)
Number of subjects: 288
Study 25798568 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 288
Study 23127304 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point pressure release therapy (TPPRT)
Number of subjects: 52
Study 23127304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no history of PFP)
Number of subjects: 52
Study 22090049 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical varicocelectomy
Number of subjects: 84
Study 22090049 — intervention group
Group type: COMPARATOR
Intervention: Naked eye varicocelectomy
Number of subjects: 84
Study 19487823 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow strap orthosis
Number of subjects: 52
Study 19487823 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow sleeve orthosis
Number of subjects: 52
Study 19487823 — intervention group
Group type: COMPARATOR
Intervention: Wrist splint
Number of subjects: 52
Study 19487823 — intervention group
Group type: COMPARATOR
Intervention: Placebo orthosis
Number of subjects: 52